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Aortic Valve Replacement Procedure
Eliminate Post-Operative Delirium?*
David A. Wood, MDSEE PAGE 160S ince the ﬁrst human implants over a decadeago, transcatheter aortic valve replacement(TAVR) has evolved as the new standard of
care for both inoperable and carefully selected high-
risk patients with severe symptomatic aortic valve
stenosis. Initial concerns with the rates of vascular
injury, stroke, and residual paravalvular regurgita-
tion have decreased. Current data suggest that device
reﬁnements and rigorous patient screening may
further reduce some of these recognized complica-
tions with mid-term durability that is similar to surgi-
cally implanted valves.
Post-operative delirium (POD) is a signiﬁcant cause
of cardiovascular morbidity and mortality after car-
diac surgery with an incidence >30% in patients age
>70 years (1–3). Compared with surgical revasculari-
zation alone, TAVR is associated with an added risk of
POD (4–6). POD after cardiac surgery has been asso-
ciated with prolonged mechanical ventilation (7,8),
prolonged hospital length of stay, and increased
short- and long-term mortality (8–11). Multiple non-
pharmacological measures to predict and prevent
POD have been documented in the published surgical
data (12). Although few reports on the incidence and
consequences of POD following TAVR are available
(2,4,13), there is increasing interest in the potential
ancillary beneﬁts of a “simpliﬁed” transfemoral TAVR
procedure with early mobilization and streamlined
post-operative care (14–18).*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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Abawi et al. (19) present a retrospective, single-
center, observational cohort study examining the
incidence of in-hospital POD after TAVR (average age
80  7 years, logistic EuroSCORE 18  9%). Over a3-year period, the incidence of in-hospital POD was
13.4% (36 of 268 patients undergoing TAVR). However,
the rate of POD was 5-fold higher with alternative ac-
cess (18 of 40, 45%) versus transfemoral (18 of 240, 8%)
TAVR. PODwas associatedwith a prolonged in-hospital
length of stay regardless of complications. At a median
follow-up of 16 months (6 to 27 months), POD was an
independent predictor of mortality in patients under-
going transfemoral TAVR (hazard ratio: 2.81; 95% con-
ﬁdence interval: 1.16 to 6.83). Consistent with similar
prior small studies (2,4,13), alternative access was the
strongest predictor of POD, with an incidence similar to
that observed in elderly patients after SAVR (1–3). The
authors stressed that although general anesthesia was
associated with POD, its independent effect could not
be assessed because of multicollinearity with alterna-
tive access TAVR. In this retrospective study, all alter-
native access patients (40 of 40) but only 5% of
transfemoral patients (12 of 240) received general
anesthetic. All of the remaining transfemoral TAVR
patients were treated with conscious sedation and
were administered propofol and remifentanil.
Abawi et al. (19) should be commended for
focusing our attention on the incidence, predictors,
and effect of POD after TAVR. They utilized a delirium
observational score, and a trained geriatrician was
consulted to establish the diagnosis of delirium using
Diagnostic and Statistical Manual of Mental Disor-
ders, 4th Edition, criteria when the score was $3.
Unfortunately, frailty was subjectively assessed using
the informal “eyeball test” and was evident in 24%
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170of patients (63 of 268). Interestingly, the incidence
of frailty was similar between those that developed
POD (9 of 36, 25%) versus those that did not develop
POD (54 of 232, 23%; p ¼ 0.82).
Obvious questions arise: can delirium be signiﬁ-
cantly decreased or even eliminated in high-risk
patients undergoing contemporary transfemoral
TAVR? Can a fully awake procedure with objective
anatomical and functional screening criteria reduce
most complications, including POD, in elderly patients
with multiple comorbidities? The 3M TAVR (Multidis-
ciplinary, Multimodality, but Minimalist Approach
to Transfemoral Transcatheter Aortic Valve Replace-
ment) study (13 North American sites, n ¼ 800) is
currently prospectively enrolling elective trans-
femoral TAVR patients considered to be at increased
surgical risk by their respective heart teams
(NCT02287662). In contrast to Abawi et al. (19), the
default strategy is a fully awake patient, with a pre-
speciﬁed conscious sedation protocol only if re-
quired. The Vancouver Clinical Pathway, utilized in
the 3M TAVR study, also includes a simpliﬁed trans-
femoral procedure with early mobilization and next-
day discharge. The coprimary outcomes comprise
all-cause mortality and major stroke (modiﬁed Rankin
Scale of 2 or more) by 30 days as well as theproportion of patients who can be safely discharged
the next day. Multiple secondary endpoints include
short- and long-term quality of life and health eco-
nomic metrics, readmission rates, and POD with
rigorous outpatient follow-up. The preliminary results
are encouraging.
While we await the results of multicenter studies,
avoiding alternative access and general anesthesia
where possible will likely reduce the incidence of POD
in high-risk patients. TAVR warrants a clinical
pathway tailored to the unique procedure and patient
requirements that optimizes opportunities for
reducing risk and facilitates early recovery. A fully
awake transfemoral procedure with early mobiliza-
tion and next-day discharge may result in signiﬁcant
cost savings and early improvements in quality of
life; furthermore, as highlighted by Abawi et al. (19), a
signiﬁcant ancillary beneﬁt may be its ability to
reduce or even eliminate POD.
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